363 related articles for article (PubMed ID: 30893101)
1. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
2. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
3. Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy.
Khalid F; Gupta R; Gor R; Gor D; Singh V; Eltoukhy H
World J Oncol; 2023 Apr; 14(2):109-118. PubMed ID: 37188042
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system injury from novel cancer immunotherapies.
Winter SF; Vaios EJ; Dietrich J
Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
[TBL] [Abstract][Full Text] [Related]
5. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
6. Neurologic Toxicities of Immunotherapy.
Harrison RA; Majd NK; Tummala S; de Groot JF
Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
8. Neurologic Toxicities of Cancer Immunotherapies: a Review.
Harrison RA; Tummala S; de Groot J
Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
[TBL] [Abstract][Full Text] [Related]
9. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
11. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
Fishman JA; Hogan JI; Maus MV
Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
[TBL] [Abstract][Full Text] [Related]
13. Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents.
Bompaire F; Birzu C; Bihan K; Desestret V; Fargeot G; Farina A; Joubert B; Leclercq D; Nichelli L; Picca A; Tafani C; Weiss N; Psimaras D; Ricard D
Rev Neurol (Paris); 2023 Jun; 179(5):405-416. PubMed ID: 37059646
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Drugs and the Nervous System.
Santomasso BD
Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
17. Neurological complications of cancer immunotherapy (CAR T cells).
Rubin DB; Vaitkevicius H
J Neurol Sci; 2021 May; 424():117405. PubMed ID: 33773767
[TBL] [Abstract][Full Text] [Related]
18. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
19. Neurologic Complications of Cancer Immunotherapy.
Wang N
Continuum (Minneap Minn); 2023 Dec; 29(6):1827-1843. PubMed ID: 38085900
[TBL] [Abstract][Full Text] [Related]
20. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
